Amryt Pharma PLC Notice of Results (7571O)

TIDMAMYT

RNS Number : 7571O

Amryt Pharma PLC

23 August 2017

23 August 2017

AIM: AMYT

ESM: AYP

Amryt Pharma plc

("Amryt" or the "Company")

Notice of Interim Results

Amryt Pharma, the biopharmaceutical company focused on innovative therapies for patients with rare and orphan diseases, will announce interim results, covering the six months to 30 June 2017, on Monday, 4 September 2017.

For further information on an analyst briefing to be held that day, please contact KTZ Communications.

Enquiries:

 
Amryt Pharma plc                 C/o KTZ Communications 
Joe Wiley, CEO 
 Rory Nealon, CFO/COO 
 
Shore Capital                    [phone] 
Nomad and Joint Broker 
Bidhi Bhoma, Edward Mansfield 
 
Davy                             [phone] 
ESM Adviser and Joint Broker 
John Frain, Anthony Farrell 
 
Stifel                           [phone] 
Joint Broker 
Jonathan Senior, Ben Maddison 
 
KTZ Communications               [phone] 
Katie Tzouliadis, Emma Pearson 
 

About Amryt Pharma plc

(www.amrytpharma.com)

Amryt Pharma is a specialty pharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare or orphan diseases. The Company is building a diversified portfolio of commercially attractive, best-in-class, proprietary new drugs to help address some of these rare and debilitating illnesses for which there are currently no available treatments.

The Company holds an exclusive licence to sell Lojuxta (lomitapide) for adults, across the EU and other territories including the Middle East, North Africa, Turkey and Israel. Lojuxta is used to treat a rare life-threatening disease called Homozygous Familial Hypercholesterolemia, which impairs the body's ability to remove LDL cholesterol ("bad" cholesterol) from the blood. This typically results in extremely high blood LDL cholesterol levels, leading to aggressive and premature narrowing and blocking of arterial blood vessels. If left untreated, heart attack or sudden death may occur in childhood or early adulthood.

Amryt's lead drug candidate, AP101 (Episalvan), is a potential treatment for Epidermolysis Bullosa ("EB"), a rare and distressing genetic skin disorder affecting young children for which there is currently no treatment. It is currently in Phase 3 clinical trials. The global market opportunity for EB is estimated to be in excess of EUR 1.3 billion.

Amryt's earlier stage product AP102 is focused on developing novel, next generation somatostatin analogue ("SSA") peptide medicines for patients with rare neuroendocrine diseases, where there is a high unmet medical need, including acromegaly and Cushing's disease.

The Company joined AIM and Dublin's ESM in April 2016 following the reverse takeover of Fastnet Equity PLC.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NORSEWSWDFWSEEA

(END) Dow Jones Newswires

August 23, 2017 03:30 ET (07:30 GMT)